Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

(2011) Peter A Fasching et al.   BMC CANCER

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups

(2010) Mohammed A. Aleskandarany et al.   BREAST CANCER RESEARCH AND TREATMENT

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

(2009) Marie Klintman et al.   MODERN PATHOLOGY

Evaluation of estrogen receptor α and β and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers

(2008) Fabíola E. Rosa et al.   HUMAN PATHOLOGY

Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status

(2007) Jisen Dai et al.   BREAST